Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
复制标题
DOI：
10.1002/jmv.26397
复制
发表时间：
2020-08-16
影响因子：
12.7
通讯作者：
Kim, Seungtaek
中科院分区：
文献类型：
--
作者：
Ko, Meehyun;Jeon, Sangeun;Kim, Seungtaek
药物重新定位是当前疫情防控的有效途径。在此之前，我们发现了24种fda批准的药物，这些药物对Vero细胞中的严重急性呼吸综合征冠状病毒2表现出显著的抗病毒作用。由于抗病毒效果可以在不同的细胞系中改变，我们开发了一种针对人肺细胞的抗病毒筛选试验，这比Vero细胞更合适。抗病毒活性对比分析显示，纳莫司他对人肺细胞的抗病毒活性最强（IC50 = 0.0022 μ M）。
Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 mu M).